Expression and functional analysis of glycosyl-phosphatidyl inositol- linked CD46 in transgenic mice

Transplantation

Volumn 66, Issue 11, 1998, Pages 1401-1406

  Shinkel, Trixie A ^a   Cowan, Peter J ^a   Barlow, Helen ^a   Aminian, Atousa ^a   Romanella, Margarita ^a   Lublin, Douglas M ^b   Pearse, Martin J ^a   D'Apice, Anthony J F ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C4B; DECAY ACCELERATING FACTOR; GLYCOSYLPHOSPHATIDYLINOSITOL; MEMBRANE COFACTOR PROTEIN; NERVE CELL ADHESION MOLECULE; REGULATOR PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; FUNCTIONAL ANATOMY; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATOR GENE; TRANSGENIC MOUSE; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD46; CELL ADHESION MOLECULES; COLORING AGENTS; COMPLEMENT INACTIVATOR PROTEINS; ENDOTHELIUM, VASCULAR; FLUORESCEIN-5-ISOTHIOCYANATE; GENE EXPRESSION; GLYCOSYLPHOSPHATIDYLINOSITOLS; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; PROMOTER REGIONS (GENETICS);

EID: 0032535218     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199812150-00001     Document Type: Article

References (44)

1. Platt JL, Vercellotti GM, Dalmasso AP, et al. Transplantation of discordant xenografts: a review of progress. Immunol Today 1990; 11: 450.
2. Platt JL, Fischel RJ, Matas AJ, Reif SA, Bolman RM, Bach FH. Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation 1991; 52: 214.
3. Seya T, Turner JR, Atkinson JP. Purification and characterization of a membrane protein (gp 45-70) that is a cofactor for cleavage of C3b and C4b. J Exp Med 1986; 163: 837.
4. Fujita T, Inoue T, Ogawa K, IIda K, Tamura N. The mechanism of action of decay-accelerating factor (DAF). J Exp Med 1987; 166: 1221.
5. Meri S, Morgan BP, Davies A, et al. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5B-8 catalysed insertion of C9 into lipid bilayers. Immunology 1990; 71: 1.
6. Lachmann PJ. The control of homologous lysis. Immunol Today 1991; 12: 312.
7. Atkinson JP, Farries T. Separation of self from non-self in the complement system. Immunol Today 1987; 8: 212.
8. Van Denderen BJW, Pearse MJ, Katerelos M, et al. Expression of functional decay-accelerating factor (CD55) in transgenic mice protects against human complement-mediated attack. Transplantation 1996; 61: 582.
9. Thorley Br, Milland J, Christiansen D, et al. Transgenic expression of a CD46 (membrane cofactor protein) minigene: studies of xenotransplantation and measles virus infection. Eur J Immunol 1997; 27: 726.
10. Cary N, Moody J, Yannoutsos N, Wallwork J, White D. Tissue expression of human decay accelerating factor, a regulator of complement activation expressed in mice: a potential approach to inhibition of hyperacute xenograft rejection. Transplant Proc 1993; 25: 400.
11. Diamond LE, Oldham ER, Platt JL, et al. Cell- and tissue-specific expression of a human CD59 minigene in transgenic mice. Transplant Proc 1994; 26: 1239.
12. Somerville CA, Kyriazis AG, Mckenzie M, Allison J, Pearse MJ, d'Apice AJF. Functional expression of human CD59 in transgenic mice. Transplantation 1994; 58: 1430.
13. Cowan PJ, Shinkel TA, Witort EJ, Barlow H, Pearse MJ, Dapice AJF. Targeting gene expression to endothelial cells in transgenic mice using the human intercellular adhesion molecule 2 promoter. Transplantation 1996; 62: 155.
14. Seya T, Ballard L, Bora N, McNearney T, Atkinson JP. Distribution of membrane cofactor protein (MCP) of complement on human peripheral blood cells. Eur J Immunol 1988; 18: 1289.
15. McNearney T, Ballard L, Seya T, Atkinson JP. Membrane cofactor protein of complement is present on human fibroblast, epithelial and endothelial cells. J Clin Invest 1989; 84: 538.
16. Oglesby TJ, Allen CJ, Liszewski MK, White DJG, Atkinson JP. Membrane cofactor protein (CD46) protects cells from complement-mediated attack by an intrinsic mechanism. J Exp Med 1992; 175: 1547.
17. Lublin DM, Coyne KE. Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage. J Exp Med 1991; 174: 35.
18. White DJG, Oglesby T, Liszewski MK, et al. Expression of human decay accelerating factor or membrane cofactor protein genes on mouse cells inhibits lysis by human complement. Transplant Proc 1992; 24: 474.
19. Loveland BE, Johnstone RW, Russell SM, Thorley BR, McKenzie IFC. CD46 (MCP) confers protection from lysis by xenogeneic antibodies. Transplant Proc 1993; 25: 396.
20. Iwata K, Seya T, Ariga H, Nagasawa S. Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary: comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein. J Immunol 1994; 152: 3436.
21. Miyagawa S, Shirakura R, Iwata K, et al. Effects of transfected complement regulatory proteins, MCP, DAF, and MCP/DAF hybrid, on complement-mediated swine endothelial cell lysis. Transplantation 1994; 58: 834.
22. Ijzermans JNM, Schraa EO, Bonthuis F, Yannnoutsos N, Marquet RL. In vivo evaluation of human membrane cofactor protein in transgenic mice. Transplant Proc 1996; 28: 671.
23. Oldham ER, Velardo MA, Platt JL, Logan JS, Diamond L. High-level tissue specific expression of human CD59, MCP, and DAF proteins from genomic clones in transgenic mice. Transplant Proc 1996; 28: 693.
24. Yannoutsos N, Ijzermans JN, Harkes C, et al. A membrane cofactor protein transgenic mouse model for the study of discordant xenograft rejection. Genes Cells 1996; 1: 409.
25. Marquet RL, van Stijn I, van den Tol PM, Bonthuis F, Yannoutsos N, Ijzermans JNM. Human CD46 but not CD59 in transgenic mice protects against hyperacute rejection evoked by ex vivo perfusion with human serum. Transplant Proc 1997; 29: 931.
26. Kagan D, Platt J, Logan J, Byrne GW. Expression of complement regulatory factors using heterologous promoters in transgenic mice. Transplant Proc 1994; 26: 1242.
27. McCurry KR, Kooyman DL, Alvarado CG, et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nature Med 1995; 1: 423.
28. Mulder LCF, Ciccopiedi E, Mora M, et al. Livers of mice transgenic for human CD46 are protected from human complement attack. Transgenics 1995; 1: 629.
29. Mora M, Mulder LCF, Lazzeri M, et al. Protection from complement-mediated injury in livers and kidneys of transgenic mice expressing human complement regulators. Xenotransplantation 1996; 3: 63.
30. Miyagawa S, Ikawa M, Kominami K, et al. Difference of expression levels between gene technological product delta CYT-MCP (CD46) and intact MCP (CD46) in transgenic mice. Transplant Proc 1996; 28: 585.
31. Miyagawa S, Ikawa M, Kominami K, et al. The regulation of membrane cofactor protein (CD46) expression in transgenic mice: the importance of the first 125 BP of the 3′ untranslated region. Transplant Proc 1997; 29: 941.
32. Mulder LCF, Rossini M, Mora M. Human CD46 aberrant splicing in transgenic mice. Gene 1997; 186: 83.
33. Sparrow RL, Mckenzie IFC. HuLy-m5: a unique antigen physically associated with HLA molecules. Human Immunol 1983; 7: 1.
34. Romanella M, Aminian A, Adam WR, Pearse MJ, Dapice AJF. Involvement of both the classical and alternate pathways of complement in an ex vivo model of xenograft rejection. Transplantation 1997; 63: 1021.
35. Cowan PJ, Shinkel TA, Aminian A, et al. High-level co-expression of complement regulators on vascular endothelium in transgenic mice: CD55 and CD59 provide greater protection from human complement-mediated injury than CD59 alone. Xenotransplantation (in press).
36. Kojima A, Iwata K, Masumoto M, Ariga H, Atkinson JP, Nagasawa S. Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis. J Immunol 1993; 151: 1519.
37. Christiansen D, Milland J, Thorley BR, Mckenzie IFC, Loveland BE. A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitro. Eur J Immunol 1996; 26: 578.
38. Zhao ZX, Termignon JL, Cardoso J, et al. Hyperacute xenograft rejection in the swine-to-human donor-recipient combination: in vitro analysis of complement activation. Transplantation 1994; 57: 245.
39. Miyagawa S, Hirose H, Shirakura R, et al. The mechanism of discordant xenograft rejection. Transplantation 1988; 46: 825.
40. Zhao Z, Termignon JL, Cardoso J, et al. Hyperacute xenograft rejection in the swine-to-human donor-recipient combination. Transplantation 1994; 57: 245.
41. McCurry KR, Kooyman DL, Diamond LE, Byrne GW, Logan JS, Platt JL. Transgenic expression of human complement regulatory proteins in mice results in diminished complement deposition during organ xenoperfusion. Transplantation 1995; 59: 1177.
42. Byrne G, McCurry KR, Martin MJ, McClellan SM, Platt JL, Logan JS. Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation 1997; 63: 149.
43. Tearle RG, Tange MJ, Zannettino ZL, et al. The α-1,3-galactosyltransferase knockout mouse: implications for xenotransplantation. Transplantation 1996; 61: 13.
44. Chen C-G, Fisicaro N, Shinkel TA, et al. Reduction in Gal-α1,3-Gal epitope expression in transgenic mice expressing human H-transferase. Xenotransplantation 1996; 3: 69.